Historically, cachexia has not been fully understood. Also known as wasting syndrome, cachexia is often incorrectly viewed as simply an inevitable side effect to cancer and other chronic conditions.

29, on Zoom. Zimmers' research focuses on cachexia — systemic inflammation and dysmetabolism afflicting patients with burns, trauma, injury, and chronic diseases including advanced cancer. Abstract: ...

Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Although the first GLP-1 drug was approved by the US Food and Drug Administration (FDA) in the early 2000s, it wasn't until a ...

In a recent study, researchers demonstrated that Z526, a novel dithiocarbamate-like compound, mitigates cancer-associated cachexia (CAC) both in vitro and in vivo. Oral administration of Z526 ...

vip.163.com Background Cancer cachexia is a complex metabolic syndrome characterised by a loss of muscle with or without loss of fat mass, and is associated with high morbidity and mortality. Despite ...

Uncovering the role of oncogenic HER2 variants as drivers of pancreatic cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a ...